Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
It is very uncertain whether induced hypertension changes death or dependency (primary outcome) compared with placebo or no intervention (very low certainty).
It is very uncertain whether induced hypertension changes proportion of participants with ≥ 1 serious adverse events compared with placebo or no intervention (very low certainty).
It is very uncertain whether induced hypertension changes delayed cerebral ischaemia compared with placebo or no intervention (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether lowered blood pressure changes death from all causes (primary outcome) compared with placebo (very low certainty).
The review found no eligible studies for this question.
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (any cause) compared with control (placebo or standard care) (moderate certainty).
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower cardiovascular and cerebrovascular morbidity compared with control (placebo or standard care) (moderate certainty).
Aldosterone antagonists (spironolactone or eplerenone) showed no clear difference in hyperkalaemia compared with control (placebo or standard care) (low certainty).
Aldosterone antagonists (spironolactone or eplerenone) probably leads to higher gynaecomastia compared with control (placebo or standard care) (moderate certainty).
Indomethacin leads to lower failure of PDA closure within 1 week of administration of the first… compared with placebo or control (high certainty).
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 28 days compared with placebo or control (low certainty).
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 36 weeks' gestation compared with placebo or control (low certainty).
Indomethacin showed no clear difference in all‐cause neonatal mortality before hospital discharge compared with placebo or control (moderate certainty).
Indomethacin showed no clear difference in proportion of infants requiring surgical ligation of PDA compared with placebo or control (moderate certainty).